Barclays Lowers Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $200.00

Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) had its price target decreased by Barclays from $230.00 to $200.00 in a research report sent to investors on Friday, Benzinga reports. Barclays currently has an overweight rating on the specialty pharmaceutical company's stock.

A number of other brokerages have also recently commented on JAZZ. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. Stifel Nicolaus lifted their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a buy rating in a research note on Friday, March 15th. Cantor Fitzgerald reaffirmed an overweight rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com cut shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday. Finally, Needham & Company LLC reaffirmed a buy rating and set a $222.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of Moderate Buy and an average target price of $192.75.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $0.72 on Friday, hitting $110.01. The company had a trading volume of 693,760 shares, compared to its average volume of 615,282. Jazz Pharmaceuticals has a 12-month low of $103.01 and a 12-month high of $146.70. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The stock's 50-day simple moving average is $116.44 and its 200 day simple moving average is $121.10. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of 22.68, a P/E/G ratio of 1.52 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 28.08% and a net margin of 8.61%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. As a group, equities research analysts expect that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the business's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the company's stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the company's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in JAZZ. SG Americas Securities LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter worth $611,000. Asset Management One Co. Ltd. lifted its stake in Jazz Pharmaceuticals by 12.0% in the 3rd quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company's stock valued at $3,640,000 after buying an additional 3,004 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in Jazz Pharmaceuticals by 10.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company's stock worth $1,304,000 after buying an additional 962 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in Jazz Pharmaceuticals by 2.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 10,587 shares of the specialty pharmaceutical company's stock worth $1,370,000 after buying an additional 238 shares in the last quarter. Finally, Forsta AP Fonden raised its holdings in shares of Jazz Pharmaceuticals by 15.2% during the third quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company's stock valued at $2,848,000 after acquiring an additional 2,900 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.